British drugmaker AstraZeneca has made clear its intent to rapidly scale production of the University of Oxford’s COVID-19 vaccine hopeful despite a dearth of clinical data to support its use. Now, with an eye-popping deal worth three-quarters of a billion dollars, AstraZeneca is putting its money where its mouth is.
ZURICH (Reuters) – Roche plans to test if mixing its anti-inflammation drug Actemra with Gilead Sciences Inc’s anti-viral treatment remdesivir works better against severe COVID-19 pneumonia than remdesivir alone, the Swiss drugmaker said on Thursday.
In the hunt for a COVID-19 therapy, some researchers have hit upon a combination of antimalarial hydroxychloroquine and antibiotic azithromycin as a potential answer. So far, clinical results have been mixed at best—but demand for azithromycin has still been sky-high, and drugmakers are feeling the pinch.
(Reuters) – Abbott Laboratories Inc (ABT.N) said on Thursday a recent ramp up in coronavirus tests production would help it ride out a tough current quarter as the outbreak chokes demand for its other diagnostic kits.
June 2 (Reuters) – Pfizer Inc said on Tuesday it will invest up to $500 million into publicly traded drug developers to fund their treatment candidates and provide access to the U.S. drugmaker’s scientific expertise.
(Reuters) – Johnson & Johnson said on Thursday it had struck a deal with Emergent BioSolutions Inc to use its manufacturing facilities to help in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.
(Reuters) – Britain’s AstraZeneca is testing a diabetes drug as a potential treatment for COVID-19 patients who also had existing heart and kidney problems, its second trial of an approved therapy to help treat the disease caused by the coronavirus.
French drugmaker Sanofi expects to produce up to 600 million doses of its coronavirus vaccine next year if its clinical trials with GSK go as planned, CEO Paul Hudson said Friday.
The French drug giant Sanofi said Tuesday that it plans to use technology from GlaxoSmithKline to accelerate the development of its experimental vaccine against the novel coronavirus, SARS-CoV-2.
